Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

NCT02642042 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

KRAS Gene Mutation
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis
DRUG: Trametinib

Sponsor

National Cancer Institute (NCI)